Aptevo Therapeutics (APVO) is a clinical-stage pharmaceutical company focused on developing novel therapies targeting cancer indications.In the past week, the company’s stock lost 79.0%. This downside came after management came out with a secondary issue of 3.4 million shares of its common stock to the public at an issue price of $1.35 per share, amounting to $4.6 million in gross proceeds. The issue was closed on Apr 15.Per the public offer’s terms, each common stock will be accompanied by two warrants. Ea ...

Aptevo Therapeutics (NASDAQ:APVO) stock is falling on Thursday after the clinical-stage biotechnology company priced a public offering for its shares.That public offering has Aptevo Therapeutics selling 3.4 million shares of APVO stock at a price of $1.35 each. The shares also come with warrants to purchase another 6.8 million shares of the company’s stock.Aptevo Therapeutics notes that the exercise price for the warrants in this offer is also $1.35 per share. The warrants are exercisable immediately and ex ...

Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA – March 5, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune ...

th | --- | --- | --- | |------------------------------------------------------|------------------|-----------------------------------------------------------------------| | Title of Each Class | Trading Symbol | Name of Exchange on Which Registered | | Common Stock, $0.001 par value per share | APVO | The Nasdaq Stock Market LLC (The Nasdaq Capital Market) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | |-----------------------------------------------------------------------------|-------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | |------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | |------------------------------------------------------------------------------------------------------ ...

th | --- | --- | --- | |-----------------------------------------------------------------------------|------------------|-----------------------------------------------------------------------| | | | | | Securities registered pursuant to Section 12(b) of the Act: | | | | Title of Each Class | Trading Symbol | Name of Exchange on Which Registered | | Common Stock, $0.001 par value per share | APVO | The Nasdaq Stock Market LLC (The Nasdaq Capital Market) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was ...